ERBB2 and breast carcinoma: DESTINY-Breast 02 was a phase 3 trial comparing T-DXd vs treatment of physician's choice in 608 patients with pretreated (median 2–3 prior lines of treatment and nearly all received prior trastuzumab emtansine) HER2-positive advanced breast cancer [34].